Latest Headlines

1. YD Bio And EG BioMed Expand U.S. Access To OkaiDx™, A cfDNA Methylation Blood Test For Post Treatment Breast Cancer Monitoring 11/5/2025

   YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc.

2. Illumina And Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights 11/5/2025

   Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7M in seed funding led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures, Alumni Ventures, and AME Cloud Ventures.

3. QIAGEN To Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio Into Highly Scalable Single-Cell Solutions 11/4/2025

   QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.

4. Countable Labs Announces Additional Modules For Countable PCR Expanding Its Utility For Translational Research, Cell And Gene Therapy Manufacturing, And Diagnostic Development 11/4/2025

   Countable Labs, the developer of Countable PCR, the leading PCR innovation transforming how science measures biology, announced the launch of the RNA Module for Countable PCR.

5. SimplyTest Partners With Evexia Diagnostics To Expand Access To PERIO And 4-Point Cortisol Tests For Functional And Integrative Health Practitioners 11/4/2025

   SimplyTest is proud to announce a new partnership with Evexia Diagnostics, a premier provider of diagnostic laboratory services for functional and integrative medicine.

6. QuidelOrtho Receives FDA 510(k) Clearance For VITROS™ Immunodiagnostic Products hs Troponin I Assay 11/3/2025

   The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the "VITROS hs Troponin I Assay").

7. Co-Diagnostics To Integrate And Implement Proprietary Artificial Intelligence Technology Into Co-Dx™ Primer Ai™ Platform 11/3/2025

   Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence ("AI") business unit, led by Chief Technology & AI Officer Christopher Thurston, to integrate the Company's existing and planned AI applications into the Co-Dx™ Primer Ai™ platform.

8. AIxMed And PathNet Partnership: Advancing Digital Pathology With AI-Powered Urine Cytology 11/3/2025

   AIxMed, a recognized innovator in AI diagnostics for urine cytology, and PathNet, a leading diagnostic laboratory, announced a strategic partnership.

9. First In The United States To Offer New Testicular Cancer Blood Test 11/3/2025

   UC San Diego Health is the first health system in the country to offer a new blood test for testicular cancer, a major advancement in the treatment and surveillance of patients with the disease.

10. BD Receives FDA 510(k) Clearance And CE-IVDR Certification For High-Throughput Enteric Bacterial Panels On BD COR™ System 11/3/2025

    BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System.